Pharmacokinetic studies of [14C]-flumecinol in humans

I. Klebovich, J. Csetenyi, S. Kerpel-Fronius, L. Vereczkey

Research output: Article


The pharmacokinetics of 14C-labelled 3-trifluoromethyl-α-ethylbenzhydrol (flumecinol, RGH-3332, Zixoryn®), a hepatic enzyme inducer, has been studied in 6 male healthy volunteers after a single oral dose of 100 mg (11.1 Mbq; 300 μCi). Flumecinol concentration in plasma was determined (0-96 h) by capillary gas-liquid chromatography. Total radioactivity was assayed by liquid scintillation counting. The peak concentration of unchanged flumecinol in the plasma (130.2 ± 37.7 ng/ml S.D.) was detected 2.1 h after dosing. The maximum total radioactivity concentration (1414.4 ± 158.9 ng eq./ml) was found at 2.3 h. The ratio of the plasma radioactivity level to unchanged flumecinol indicated a rapid metabolic transformation and a marked first-pass effect in man. A two-compartment open model was constructed to describe the pharmacokinetics of the drug. The unchanged drug was eliminated from plasma with a biological half-life of 20.7 ± 1.8 h giving a total body clearance value of 100.9 ± 33.8 l/h. The volume of distribution of flumecinol was found to be 41.4 ± 18.4 l/kg. However, the biological half-life of total radioactivity was much longer (35.2 ± 11.9 h) than that of the decrease of unchanged drug. The value of total body clearance (4.1 ± 0.6 l/h) and volume of distribution (3.2 ± 1.6 l/kg) were found to be much lower than that of unchanged flumecinol. Radioactivity excreted with urine was 78.8 ± 5.9% and with faeces 12.0 ± 5.3% during 120 h.

Original languageEnglish
Pages (from-to)368-371
Number of pages4
JournalArzneimittel-Forschung/Drug Research
Issue number3
Publication statusPublished - jan. 1 1987


ASJC Scopus subject areas

  • Drug Discovery

Cite this